RICARDO ARTURO SARACCO-ALVAREZ

Dr. RICARDO ARTURO SARACCO-ALVAREZ

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
RERaul Escamilla
Raul Escamilla
BCBeatriz Camarena
Beatriz Camarena
RSRICARDO ARTURO SARACCO-ALVAREZ
RICARDO ARTURO SARACCO-ALVAREZ
AOAna Fresán Orellana
Ana Fresán Orellana
SHSandra Hernández
Sandra Hernández
AAAlejandro Aguilar-García
Alejandro Aguilar-García
Purpose: The efficacy of schizophrenia treatments using antipsychotics (APs) has long been established, but the benefit obtained by several patients using conventional APs (typical or atypical) has not been enough. Currently, the genetic study of the primary mechanisms of action of the APs has been focused on the dopaminergic pathways. The objective of this study was to determine if the response phenotypes (responder, resistance to treatment, and ultra-resistance to treatment groups) are associated with six single-nucleotide polymorphisms: COMT (Val158Met), DRD2 (A-241G, C376G, C939T, Taq1A), and DRD3 (Ser9Gly). Patients and methods: We classified the patients through a retrospective/prospective methodology to define response phenotypes. Results: COMT/Val158Met and DRD3/Ser9Gly were associated with the responder group (P<0.05). The single-nucleotide polymorphism A-241G of DRD2 gene was related with the resistant-to-treatment group (P<0.001). Finally, Met/Met of COMT and Ser/Gly of DRD3 genes showed a predictive effect associated with the resistant-to-treatment phenotype. Conclusion: Further analyses should be performed to validate these genetic markers as mediators for the response to APs.

Verified
Journal Article
Open access
PDF file
RARuth Alcalá-Lozano
Ruth Alcalá-Lozano
RCRocio Carmona-Hernández
Rocio Carmona-Hernández
Ana Gabriela Ocampo RomeroAna Gabriela Ocampo Romero
Ana Gabriela Ocampo Romero
ASAdriana Leticia Sosa-Millán
Adriana Leticia Sosa-Millán
EMErik Morelos-Santana
Erik Morelos-Santana
JGJorge Julio Gonzalez-Olvera
Jorge Julio Gonzalez-Olvera
In amnestic mild cognitive impairment (aMCI), neuroinflammation evolves during disease progression, affecting microglial function and potentially accelerating the pathological process. Currently, no effective treatment exists, leading to explorations of various symptomatic approaches, though few target the underlying physiological mechanisms. Modulating inflammatory processes may be critical in slowing disease progression. Cognitive stimulation (CS) and transcranial direct current stimulation (tDCS) applied to the left dorsolateral prefrontal cortex (l-DLPFC) show promise, but the results are heterogeneous. Thus, a randomized, double-blind, placebo-controlled clinical trial is currently underway. The first-stage results were examined after three weeks of intervention in two groups: active tDCS combined with CS and sham tDCS combined with CS. Twenty-two participants underwent two assessments: T0 (baseline) and T1 (after 15 sessions of tDCS, active or sham, and 9 sessions of CS). The results demonstrated that CS improved cognition, increased brain-derived neurotrophic factor (BDNF) levels, and reduced peripheral proinflammatory cytokine levels (interleukin IL-6 and chemokine CX3CL1) in serum. This decrease in IL-6 may promote microglial proliferation and survival as a modulatory effect response, while the increase in BDNF might suggest a regulatory mechanism in microglia–neuron interaction responses. However, tDCS did not enhance the cognitive or modulatory effects of CS, suggesting that longer interventions might be required to achieve substantial benefits.

24 August 2021 in Complex Psychiatry
Verified
Journal Article
Open access
PDF file
BCBeatriz Camarena
Beatriz Camarena
EAElizabeth G. Atkinson
Elizabeth G. Atkinson
MBMark Baker
Mark Baker
CBClaudia Becerra-Palars
Claudia Becerra-Palars
LCLori B. Chibnik
Lori B. Chibnik
KKKarestan C. Koenen
Karestan C. Koenen
No large-scale genome-wide association studies (GWASs) of psychosis have been conducted in Mexico or Latin America to date. Schizophrenia and bipolar disorder in particular have been found to be highly heritable and genetically influenced. However, understanding of the biological basis of psychosis in Latin American populations is limited as previous genomic studies have almost exclusively relied on participants of Northern European ancestry. With the goal of expanding knowledge on the genomic basis of psychotic disorders within the Mexican population, the National Institute of Psychiatry Ramón de la Fuente Muñiz (INPRFM), the Harvard T.H. Chan School of Public Health, and the Broad Institute’s Stanley Center for Psychiatric Research launched the Neuropsychiatric Genetics Research of Psychosis in Mexican Populations (NeuroMex) project to collect and analyze case-control psychosis samples from 5 states across Mexico. This article describes the planned sample collection and GWAS protocol for the NeuroMex study. The 4-year study will span from April 2018 to 2022 and aims to recruit 9,208 participants: 4,604 cases and 4,604 controls. Study sites across Mexico were selected to ensure collected samples capture the genomic diversity within the Mexican population. Blood samples and phenotypic data will be collected during the participant interview process and will contribute to the development of a local biobank in Mexico. DNA extraction will be done locally and genetic analysis will take place at the Broad Institute in Cambridge, MA. We will collect extensive phenotypic information using several clinical scales. All study materials including phenotypic instruments utilized are openly available in Spanish and English. The described study represents a long-term collaboration of a number of institutions from across Mexico and the Boston area, including clinical psychiatrists, clinical researchers, computational biologists, and managers at the 3 collaborating institutions. The development of relevant data management, quality assurance, and analysis plans are the primary considerations in this protocol article. Extensive management and analysis processes were developed for both the phenotypic and genetic data collected. Capacity building, partnerships, and training between and among the collaborating institutions are intrinsic components to this study and its long-term success.

29 August 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
YFYvonne Flores-Medina
Yvonne Flores-Medina
RBRegina Avila Bretherton
Regina Avila Bretherton
JESUS RAMIREZ-BERMUDEZJESUS RAMIREZ-BERMUDEZ
JESUS RAMIREZ-BERMUDEZ
RSRICARDO ARTURO SARACCO-ALVAREZ
RICARDO ARTURO SARACCO-ALVAREZ
MFMónica Flores-Ramos
Mónica Flores-Ramos
A two-factor account has been proposed as an explanatory model for the formation and maintenance of delusions. The first factor refers to a neurocognitive process leading to a significant change in subjective experience; the second factor has been regarded as a failure in hypothesis evaluation characterized by an impairment in metacognitive ability. This study was focused on the assessment of metacognition in patients with schizophrenia. The aims of the study were to measure the overconfidence in metacognitive judgments through the prediction of word list recall and to analyze the correlation between basic neurocognition (memory and executive function) and metacognition through a metamemory test and the severity of psychotic symptoms. Method: Fifty-one participants with a diagnosis of schizophrenia were evaluated. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of psychiatric symptoms, and the subtest of metamemory included in the Executive Functions and Frontal Lobe-2 battery (BANFE-2) was used to evaluate overconfidence and underestimation errors, intrusion and perseverative response, total volume of recall, and Brief Functioning Assessment Scale (FAST) for social functioning. Results: The strongest correlation is observed between overconfidence errors and the positive factor of the PANSS (r = 0.774, p < 0.001). For the enter model in the multiple linear regression (r = 0.78, r2 = 0.61; F = 24.57, p < 0.001), the only significant predictor was overconfidence errors. Conclusion: Our results highlight the relevance of a metacognitive bias of overconfidence, strongly correlated with psychotic symptoms, and support the hypothesis that metacognitive defects contribute to the failure to reject contradictory evidence. From our perspective, these findings align with current mechanistic models of schizophrenia that focus on the role of the prefrontal cortex.

9 June 2020 in Neuropsychobiology
Verified
Journal Article
Closed access
PDF file
AMAlejandra Mondragón-Maya
Alejandra Mondragón-Maya
YFYvonne Flores-Medina
Yvonne Flores-Medina
JSJuan Silva-Pereyra
Juan Silva-Pereyra
DRDaniela Ramos-Mastache
Daniela Ramos-Mastache
GYGuillermina Yáñez-Téllez
Guillermina Yáñez-Téllez
RSRICARDO ARTURO SARACCO-ALVAREZ
RICARDO ARTURO SARACCO-ALVAREZ
Introduction: Schizoaffective disorder (SA) is classified into bipolar (bSA) and depressive (dSA) subtypes. Although clinical differences between both have been reported, there is no clear information regarding their specific cognitive profile. Objective: To compare neurocognition between SA subtypes and schizophrenia (SC). Methods: A total of 61 patients were assessed and divided into 3 groups: 35 SC, 16 bSA, and 10 dSA. All participants signed an informed consent letter. The MATRICS Consensus Cognitive Battery, Central and South American version was used to assess neurocognition. The study was performed at the Instituto Nacional de Psiquiatría “Ramón de la Fuente”. Participants were identified by specialized psychiatrists. Trained neuropsychologists carried out the clinical and cognitive assessment, which lasted 2 h approximately. Results: The cognitive assessment showed a significant difference in Trail Making Test part A subtest (F[2,58] = 4.043; p = 0.023]. Post hoc analyses indicated that dSA obtained a significantly higher score than SC (MD = –11.523; p = 0.018). The f test showed a large effect size (f = 0.401). No statistical differences were observed regarding other cognitive variables. Conclusions: The cognitive profile of SA subtypes and SC is similar since no differences were found in most subtests. However, dSA may be less impaired than SC in measures of processing speed. Further research with larger samples must be conducted.

15 April 2025 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
TSTonathiu Salcedo-Callado
Tonathiu Salcedo-Callado
NHNorberto Hernández-Llanes
Norberto Hernández-Llanes
RSRicardo Sánchez-Domínguez
Ricardo Sánchez-Domínguez
RSRICARDO ARTURO SARACCO-ALVAREZ
RICARDO ARTURO SARACCO-ALVAREZ
RMRodrigo Marín-Navarrete
Rodrigo Marín-Navarrete
Introduction: Identifying factors associated with depression is crucial to addressing the global rise in mental health needs. The Beck Depression Inventory II (BDI-II) has shown robustness in assessing depression, even in digital contexts. However, psychometric evidence is essential to support its use in online self-diagnosis, particularly in regions where it has not been widely employed for this purpose.Objective: This study aimed to evaluate the psychometric properties of the BDI-II for online self-diagnosis among Mexican adults.Method: Data from 58,456 medical records were analysed using Item Response Theory (IRT).Results: A good fit was found for a hierarchical confirmatory model with 1 s-order factor (overall severity) and two first-order factors (cognitive and somatic symptoms), as well as optimal accuracy estimates in both the IRT and the Classical Test Theory (CTT).Discussion: These findings support the use of the BDI-II as a reliable online screening tool for depression in self-diagnosis settings for Mexican adults.